William Blair Has Strong Forecast for Incyte FY2025 Earnings

Incyte Co. (NASDAQ:INCY - Free Report) - Equities researchers at William Blair increased their FY2025 earnings per share estimates for shares of Incyte in a report released on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will earn $4.21 per share for the year, up from their previous forecast of $4.20. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $4.86 per share.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald reissued a "neutral" rating on shares of Incyte in a report on Friday, January 10th. Truist Financial decreased their price objective on Incyte from $74.00 to $72.00 and set a "hold" rating on the stock in a report on Tuesday, March 18th. Guggenheim lowered shares of Incyte from a "buy" rating to a "neutral" rating and set a $92.00 target price for the company. in a report on Tuesday, March 18th. JMP Securities restated a "market perform" rating on shares of Incyte in a research report on Tuesday, February 11th. Finally, Stifel Nicolaus upped their price objective on shares of Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $75.13.

Remove Ads

Incyte Price Performance

Incyte stock traded up $1.34 during midday trading on Wednesday, reaching $61.92. The company had a trading volume of 4,332,207 shares, compared to its average volume of 2,264,889. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. Incyte has a 12-month low of $50.35 and a 12-month high of $83.95. The company has a market capitalization of $11.98 billion, a P/E ratio of 229.34, a P/E/G ratio of 0.41 and a beta of 0.76. The firm's fifty day simple moving average is $70.61 and its 200-day simple moving average is $70.13.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%.

Insider Buying and Selling at Incyte

In related news, EVP Sheila A. Denton sold 14,069 shares of Incyte stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares in the company, valued at approximately $1,914,561.36. This trade represents a 35.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the sale, the executive vice president now directly owns 33,567 shares in the company, valued at approximately $2,272,150.23. The trade was a 37.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,827 shares of company stock worth $3,322,618 over the last quarter. 17.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Incyte

A number of institutional investors have recently modified their holdings of the company. CWA Asset Management Group LLC purchased a new position in Incyte during the 4th quarter valued at about $1,933,000. Orion Portfolio Solutions LLC acquired a new position in shares of Incyte in the third quarter valued at approximately $770,000. Tri Ri Asset Management Corp purchased a new stake in Incyte during the 3rd quarter worth approximately $3,292,000. Cypress Capital Group acquired a new stake in Incyte during the 3rd quarter worth approximately $971,000. Finally, Bridgewater Associates LP boosted its position in Incyte by 142.8% in the 3rd quarter. Bridgewater Associates LP now owns 308,632 shares of the biopharmaceutical company's stock valued at $20,401,000 after buying an additional 181,504 shares during the period. 96.97% of the stock is owned by institutional investors and hedge funds.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.